Drug delivery systems for resveratrol, a non-flavonoid polyphenol: Emerging evidence in last decades

Ahmadi, Zahra; Mohammadinejad, Reza; Ashrafizadeh, Milad

doi:10.1016/j.jddst.2019.03.017

Cited by 101 publications

(58 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cancer is one of the most challenging disorders around the world (22)(23)(24)(25) and it appears that lung has a particular sensitivity to potentially toxic agents and damage, resulting in various lung disorders (26)(27)(28)(29). Gene therapy is considered a promising strategy in promoting the health of a number of inherited and acquired human conditions such as: cancer, diabetes, cardiovascular diseases and mental disorders (30).…”

Section: Discussionmentioning

confidence: 99%

ZEB1 and ZEB2 gene editing mediated by CRISPR/Cas9 in A549 cell line

Mohammadinejad¹,

Sassan²,

Pardakhty³

et al. 2020

BLL

View full text Add to dashboard Cite

OBJECTIVES: One of the best approaches for recognition of protein function is the induction of mutations for a gene knockout. In line with this strategy, gene editing tools allow researchers to induce these mutations. Lung cancer is one of the leading causes of death worldwide. ZEB1 and ZEB2 genes are the candidates for this disease. METHODS: The ZEB1 and ZEB2 knockout in the non-small cell lung cancer cell line (A549 cell) was investigated. Purifi cation of recombination plasmids was performed from bacteria and then was transported to the A549 cell line. The deletion of ZEB1 and ZEB2 were examined by PCR. RESULTS: The results demonstrated the mutation and deletion in ZEB1 and ZEB2 genes. Based on the fi ndings of this study, A549 cells were transfected with the vectors carrying the sgRNA/Cas9, simultaneously. The DNA fragment demonstrated the presence of indels in target sites as well as provided the potential of CRISPR/Cas9 system. CONCLUSION: CRISPR/Cas9 offers a great potential as an effi cient technique for editing of ZEB1 and ZEB2 genes in A549 cell line (Tab. 1, Fig. 6, Ref.

show abstract

Section: Discussionmentioning

confidence: 99%

ZEB1 and ZEB2 gene editing mediated by CRISPR/Cas9 in A549 cell line

Mohammadinejad¹,

Sassan²,

Pardakhty³

et al. 2020

BLL

View full text Add to dashboard Cite

show abstract

“…In recent years, a wide variety of studies have been performed in the field of drug delivery into the brain [43][44][45][46]. However, the BBB is a barrier to the successful delivery of drugs to the CNS since only a small number of molecules can cross the BBB [47].…”

Section: Nano-scale Drug Delivery To the Brainmentioning

confidence: 99%

Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics

et al. 2020

Self Cite

View full text Add to dashboard Cite

The blood–brain barrier (BBB) acts as a barrier to prevent the central nervous system (CNS) from damage by substances that originate from the blood circulation. The BBB limits drug penetration into the brain and is one of the major clinical obstacles to the treatment of CNS diseases. Nanotechnology-based delivery systems have been tested for overcoming this barrier and releasing related drugs into the brain matrix. In this review, nanoparticles (NPs) from simple to developed delivery systems are discussed for the delivery of a drug to the brain. This review particularly focuses on polymeric nanomaterials that have been used for CNS treatment. Polymeric NPs such as polylactide (PLA), poly (D, L-lactide-co-glycolide) (PLGA), poly (ε-caprolactone) (PCL), poly (alkyl cyanoacrylate) (PACA), human serum albumin (HSA), gelatin, and chitosan are discussed in detail.

show abstract

“…It is held that plant‐derived chemicals are capable of exerting antitumor activity by affecting various molecular signaling pathways (Ashrafizadeh, Ahmadi, Mohammadinejad, Kaviyani, & Tavakol, n.d.; Ahmadi & Ashrafizadeh, ; Ahmadi, Mohammadinejad, & Ashrafizadeh, ; Ahmadi, Roomiani, Bemani, & Ashrafizadeh, ; Mohammadinejad, Ahmadi, Tavakol, & Ashrafizadeh, ). Based on the modulatory impact of sulforaphane on various signaling pathways, it can be concluded that miRNAs can be considered as novel targets of sulforaphane in cancer therapy.…”

Section: Mirnas and Sulforaphanementioning

confidence: 99%

MicroRNAs as novel targets of sulforaphane in cancer therapy: The beginning of a new tale?

Rafiei

Ashrafizadeh

Ahmadi

2020

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

Effective management and treatment of cancer depend on developing novel antitumor drugs with the capability of targeting various molecular pathways. Identification and subsequent targeting of these pathways are of importance in cancer therapy. MicroRNAs (miRNAs) are small noncoding RNA molecules responsible for post‐transcriptional regulation of genes. Notably, miRNAs participate in a number of biological processes such as proliferation, apoptosis, differentiation, and cell cycle regulation. So, any impairment in the expression and function of miRNAs is associated with development of disorders, particularly cancer. Naturally occurring nutraceutical compounds have attracted much attention due to their great antitumor activity. Among them, sulforaphane isolated from Brassica oleracea (broccoli) is of interest due to its therapeutic and biological activities such as antidiabetic, antioxidant, anti‐inflammatory, hepatoprotection, and cardiprotection. Sulforaphane has demonstrated great antitumor activity and is able to significantly inhibit proliferation, viability, migration, malignancy, and epithelial‐to‐mesenchymal transition of cancer cells. These antitumor effects have widely been investigated, and it appears that there is a need for a precise review to demonstrate the molecular pathway that sulforaphane follows to exert its antitumor activity. At the present review, we focus on the modulatory impact of sulforaphane on miRNAs and exhibit that how various miRNAs in different cancers are regulated by sulforaphane.

show abstract

Drug delivery systems for resveratrol, a non-flavonoid polyphenol: Emerging evidence in last decades

Cited by 101 publications

References 126 publications

ZEB1 and ZEB2 gene editing mediated by CRISPR/Cas9 in A549 cell line

ZEB1 and ZEB2 gene editing mediated by CRISPR/Cas9 in A549 cell line

Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics

MicroRNAs as novel targets of sulforaphane in cancer therapy: The beginning of a new tale?

Contact Info

Product

Resources

About